Home › Drug Codes › Q Codes › Q2056 · CARVYKTI
Updated July 1st, 2026

CARVYKTI Q Code: Q2056

Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for Q2056, effective October 1, 2026: $594,112.255 per HCPCS billing unit, up 1.0% from $587,977.755. From CMS's final file.

?
Medicare Payment Limit ?
$587,977.755
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$587,977.755
/ HCPCS billing unit · APC 9498
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
2
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Added Date October 1, 2022
Manufacturer Janssen
Route of Administration Intravenous
Generic Status Single-Source; Branded
Dosage Form Injection, Suspension

About CARVYKTI

Carvykti is a medication aligned to the HCPCS Q Code: Q2056 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Janssen.

According to CMS Drug Use Information: Ciltacabtagene autoleucel is used to treat a certain type of cancer (multiple myeloma) that has not gotten better or that has come back after other kinds of treatment. This type of treatment is known as gene therapy. Ciltacabtagene autoleucel is made from your own white blood cells and is given only to you. The white blood cells have been changed to have a specific protein (chimeric antigen receptor-CAR) that helps your body slow or stop the growth of certain cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
57894-0111-01 Carvykti Janssen Biotech, Inc. 1 Carvykti Intravenous I njection 1000000… Login for More
57894-0111-02 Carvykti Janssen Biotech, Inc. 1 Carvykti Intravenous I njection 1000000… Login for More
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

CARVYKTI Pricing & Reimbursement

Q2056 Private Payer Reimbursement
$622,765.03 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

CARVYKTI Claims Performance

Claims from Jan 2026 – Aug 2026
Claim Denial Rate 0%
Avg. Days to File 0.0days
Avg. Days to Pay 103.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q2056 claims analytics on FocalPoint →
OnPoint Oncology

CARVYKTI CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415 Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

CMS does not include Carvykti (Q2056) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q2056. Wastage billing guide →

CARVYKTI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Relapsed or refractory multiple myeloma (adults; ≥1 prior line incl. proteasome inhibitor & immunomodulatory agent; lenalidomide-refractory)

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.
Access Full Report →

Frequently Asked Questions

Is there an available Carvykti billing and coding guide?
Our team has not identified a manufacturer-published source of billing and coding information for CARVYKTI.
Are there any available Carvykti patient assistance programs?
CARVYKTI patient assistance information can be found through Janssen. Visit Here →
Where can I find Carvykti prescribing information?
CARVYKTI prescribing information can be found at the link below: Visit Here →
Where can I find Carvykti side effect information?
Information regarding CARVYKTI's side effects can be found at MedlinePlus Visit Here →
Does billing CARVYKTI require JZ/JW wastage modifiers?
CMS does not include CARVYKTI (Q2056) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q2056. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.

Related Drug Codes

Explore billing, coding, and pricing for drugs related to CARVYKTI.

C9142AlymsysInjection, bevacizumab-maly, biosimilar, (alymsys), 10 mgAmneal BiosciencesAdded October 1, 2022C9146ELAHEREInjection, mirvetuximab soravtansine-gynx, 1 mgImmunogenAdded April 1, 2023C9147IMJUDOInjection, tremelimumab-actl, 1 mgAstrazenecaAdded April 1, 2023C9148TECVAYLIInjection, teclistamab-cqyv, 0.5 mgJanssenAdded April 1, 2023C9155EPKINLYInjection, epcoritamab-bysp, 0.16 mgGenmabAdded October 1, 2023C9163TALVEYInjection, talquetamab-tgvs, 0.25 mgJanssenAdded January 1, 2024C9165ELREXFIOInjection, elranatamab-bcmm, 1 mgPfizerAdded January 1, 2024C9169ANKTIVAInjection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgramAltor BioScience, LLCAdded October 1, 2024C9170IMDELLTRAInjection, tarlatamab-dlle, 1 mgAmgenAdded October 1, 2024C9173NYPOZIInjection, filgrastim-txid (nypozi), biosimilar, 1 microgramTanvex Biopharma USAAdded January 1, 2025